Fluorescent membrane potential assay for drug screening on Kv10.1 channel: identification of BL-1249 as a channel activator

Resting membrane potential is a bioelectric property of all cells. Multiple players govern this property, the ion channels being the most important. Ion channel dysfunction can affect cells’ resting membrane potential and could be associated with numerous diseases. Therefore, the drug discovery focus on ion channels has increased yearly. In addition to patch-clamp, cell-based fluorescent assays have shown a rapid and reliable method for searching new ion channel modulators. Here, we used a cell-based membrane potential assay to search for new blockers of the Kv10.1, a potassium channel strongly associated with cancer progression and a promising target in anticancer therapy. We found that fluoxetine and miconazole can inhibit the Kv10.1 channel in the micromolar range. In contrast, BL-1249 potentiates Kv10.1 currents in a dose-dependent manner, becoming the first molecule described as an activator of the channel. These results demonstrate that cell-based membrane potential assay can accelerate the discovery of new Kv10.1 modulators.

[1]  A. Anaya-Hernández,et al.  The Kv10.1 Channel: A Promising Target in Cancer , 2022, International journal of molecular sciences.

[2]  E. Luis,et al.  Role of gamma radiation on functional expression of the voltage-gated potassium channel Kv10.1 and its importance in the radiobiological response. , 2022, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[3]  P. Slesinger,et al.  Comparison of K+ Channel Families. , 2021, Handbook of experimental pharmacology.

[4]  A. Hernández-Cruz,et al.  Thallium-sensitive fluorescent assay reveals loperamide as a new inhibitor of the potassium channel Kv10.1 , 2021, Pharmacological Reports.

[5]  A. Mathie,et al.  Pharmacological Approaches to Studying Potassium Channels. , 2021, Handbook of experimental pharmacology.

[6]  J. Bednenko,et al.  Therapeutic Antibodies Targeting Potassium Ion Channels. , 2021, Handbook of experimental pharmacology.

[7]  L. Pardo,et al.  Overcoming challenges of HERG potassium channel liability through rational design: Eag1 inhibitors for cancer treatment , 2021, Medicinal research reviews.

[8]  L. Pardo,et al.  The EAG Voltage-Dependent K+ Channel Subfamily: Similarities and Differences in Structural Organization and Gating , 2020, Frontiers in Pharmacology.

[9]  A. Rodríguez-Menchaca,et al.  Chloroquine inhibits tumor-related Kv10.1 channel and decreases migration of MDA-MB-231 breast cancer cells in vitro. , 2019, European journal of pharmacology.

[10]  C. Lindsley,et al.  Towards a TREK-1/2 (TWIK-Related K+ Channel 1 and 2) dual activator tool compound: Multi-dimensional optimization of BL-1249. , 2019, Bioorganic & medicinal chemistry letters.

[11]  B. L. de Groot,et al.  A pharmacological master key mechanism that unlocks the selectivity filter gate in K+ channels , 2019, Science.

[12]  M. Stacey,et al.  Emerging Roles of the Membrane Potential: Action Beyond the Action Potential , 2018, Front. Physiol..

[13]  N. Prevarskaya,et al.  Ion Channels in Cancer: Are Cancer Hallmarks Oncochannelopathies? , 2018, Physiological reviews.

[14]  C. Osipo,et al.  Preclinical study of a Kv11.1 potassium channel activator as antineoplastic approach for breast cancer , 2017, Oncotarget.

[15]  Roderick MacKinnon,et al.  Cryo-EM Structure of the Open Human Ether-à-go-go-Related K+ Channel hERG , 2017, Cell.

[16]  L. Pardo,et al.  The electric fence to cell‐cycle progression: Do local changes in membrane potential facilitate disassembly of the primary cilium? , 2017, BioEssays : news and reviews in molecular, cellular and developmental biology.

[17]  Roderick MacKinnon,et al.  Structure of the voltage-gated K+ channel Eag1 reveals an alternative voltage sensing mechanism , 2016, Science.

[18]  L. Pardo,et al.  Cyclic expression of the voltage‐gated potassium channel KV10.1 promotes disassembly of the primary cilium , 2016, EMBO reports.

[19]  L. Pardo,et al.  Analysis of the expression of Kv10.1 potassium channel in patients with brain metastases and glioblastoma multiforme: impact on survival , 2015, BMC Cancer.

[20]  Michael X. Zhu,et al.  Membrane potential modulates plasma membrane phospholipid dynamics and K-Ras signaling , 2015, Science.

[21]  L. Pardo,et al.  Potassium channels in cell cycle and cell proliferation , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.

[22]  S. Gentile,et al.  Potassium channel activation inhibits proliferation of breast cancer cells by activating a senescence program , 2013, Cell Death and Disease.

[23]  S. Hahn,et al.  Effects of fluoxetine on cloned Kv4.3 potassium channels , 2013, Brain Research.

[24]  Linlang Guo,et al.  MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-à-go-go (EAG1). , 2013, European journal of cancer.

[25]  L. Pardo,et al.  Eag1 Expression Interferes with Hypoxia Homeostasis and Induces Angiogenesis in Tumors , 2008, Journal of Biological Chemistry.

[26]  H. Neels,et al.  Relevant Issues in the Monitoring and the Toxicology of Antidepressants , 2008 .

[27]  L. Pardo,et al.  Eag1 potassium channels as markers of cervical dysplasia. , 2007, Oncology reports.

[28]  C. Bever,et al.  Potassium channel blockers and openers as CNS neurologic therapeutic agents. , 2007, Recent patents on CNS drug discovery.

[29]  L. Pardo,et al.  Overexpression of Eag1 potassium channels in clinical tumours , 2006, Molecular Cancer.

[30]  Haruhiko Abe,et al.  Blockade of HERG cardiac K+ current by antifungal drug miconazole , 2005, British journal of pharmacology.

[31]  L. Pardo,et al.  Ether à go-go Potassium Channels as Human Cervical Cancer Markers , 2004, Cancer Research.

[32]  Dierk Thomas,et al.  The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. , 2002, The Journal of pharmacology and experimental therapeutics.

[33]  Yann Hode,et al.  Brain Pharmacokinetics and Tissue Distribution In Vivo of Fluvoxamine and Fluoxetine by Fluorine Magnetic Resonance Spectroscopy , 2000, Neuropsychopharmacology.

[34]  K. Lawson,et al.  Potassium channel openers as potential therapeutic weapons in ion channel disease. , 2000, Kidney international.

[35]  L. Pardo,et al.  Oncogenic potential of EAG K+ channels , 1999, The EMBO journal.

[36]  B. Sakmann,et al.  Single-channel currents recorded from membrane of denervated frog muscle fibres , 1976, Nature.

[37]  H. Curtis,et al.  Membrane resting and action potentials from the squid giant axon , 1942 .

[38]  I. Vetter,et al.  High-Throughput Fluorescence Assays for Ion Channels and GPCRs. , 2020, Advances in experimental medicine and biology.

[39]  A. Verkhratsky,et al.  History of electrophysiology and the patch clamp. , 2014, Methods in molecular biology.

[40]  J. Camacho,et al.  Astemizole: an old anti-histamine as a new promising anti-cancer drug. , 2011, Anti-cancer agents in medicinal chemistry.

[41]  S. Hahn,et al.  Open channel block of Kv3.1 currents by fluoxetine. , 2008, Journal of pharmacological sciences.

[42]  A. A. Al-badr,et al.  Miconazole nitrate: comprehensive profile. , 2005, Profiles of drug substances, excipients, and related methodology.